NASDAQ:ONC BeOne Medicines Q2 2025 Earnings Report $363.73 -4.35 (-1.18%) As of 02:57 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast BeOne Medicines EPS ResultsActual EPS$0.84Consensus EPS $0.48Beat/MissBeat by +$0.36One Year Ago EPSN/ABeOne Medicines Revenue ResultsActual Revenue$1.32 billionExpected Revenue$1.24 billionBeat/MissBeat by +$76.45 millionYoY Revenue GrowthN/ABeOne Medicines Announcement DetailsQuarterQ2 2025Date8/6/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile BeOne Medicines Earnings HeadlinesHead to Head Contrast: BeOne Medicines (NASDAQ:ONC) versus GSK (NYSE:GSK)September 22 at 4:45 AM | americanbankingnews.comBeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 23 at 1:00 AM | Banyan Hill Publishing (Ad)The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring DealSeptember 5, 2026 | finance.yahoo.comBeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare ConferenceSeptember 1, 2026 | finance.yahoo.comBeOne Medicines Reaches US Accord on Drug Access, Domestic ManufacturingAugust 31, 2026 | finance.yahoo.comSee More BeOne Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email. Email Address About BeOne MedicinesBeOne Medicines (NASDAQ:ONC) Ltd. is a global biotechnology company focused on the discovery, development and commercialization of medicines for cancer and other serious diseases. The company works across research, clinical development, manufacturing and commercialization, with the goal of expanding access to innovative treatments in markets around the world. BeOne’s commercial portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat certain B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy approved in multiple markets for several cancer indications. The company also maintains a broad oncology pipeline spanning hematologic cancers and solid tumors, including internally developed and partnered programs. Founded in 2010 as BeiGene, the company adopted the name BeOne Medicines in 2025 to reflect its global focus. BeOne serves patients and healthcare providers in the United States, China, Europe and other international markets. John V. Oyler is the company’s co-founder, chairman and chief executive officer.View BeOne Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
